Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

CGRP and migraine; from bench to bedside

Research output: Contribution to journalReviewResearchpeer-review

  1. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants

    Research output: Contribution to journalReviewResearchpeer-review

  2. Exercise training in metabolic myopathies

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Neuropathies optiques héréditaires

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP

    Research output: Contribution to journalReviewResearchpeer-review

  2. Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Identifying New Antimigraine Targets: Lessons from Molecular Biology

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Migraine treatment has reached a new era with the development of drugs that target the trigeminal neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. The CGRP related therapies offer considerable improvements over existing drugs as they are the first to be designed to act on the trigeminal pain system, more specific and with few adverse events. Small molecule CGRP receptor antagonists, such as rimegepant and ubrogepant, are effective for the acute treatment of migraine headache. In contrast, monoclonal antibodies against CGRP or the CGRP receptor are beneficial for the prophylactic treatments in chronic migraine. Here I will provide a historical overview of the long path that led to their successful development. In addition, I will discuss aspects on the biology of CGRP signalling, the role of CGRP in migraine headache, the efficacy of CGRP targeted treatment, and synthesize what currently is known about the role of CGRP in the trigeminovascular system.

Original languageEnglish
JournalRevue Neurologique
Volume177
Issue number7
Pages (from-to)785-790
Number of pages6
ISSN0035-3787
DOIs
Publication statusPublished - Sep 2021
Externally publishedYes

    Research areas

  • CGRP, CLR, CTR, RAMPs, Receptors

ID: 67398836